IEX Stock Recent News

IDEX Biometrics ASA informs of primary insider transactions as listed in the attached notifications. For further information contact: Marianne Bøe, Head of Investor Relations, Tel: +47 91800186 Kristian Flaten, CFO, Tel: +47 95092322 E-mail: ir@idexbiometrics.com This information is subject to the disclosure requirements pursuant to Article 19 of the EU Market Abuse Regulation and Section 5-12 of the Norwegian Securities Trading Act.

Reference is made to the Extraordinary General Meeting in IDEX Biometrics ASA ("IDEX" or the "Company") on 11 April 2025, where all proposed resolutions were approved.

IDEX Biometrics ASA held an extraordinary general meeting on 11 April 2025. 268,077,252 million shares or 32.24 % of the capital was represented at the meeting.

Idex (IEX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

IEX benefits from strength in its Fluid & Metering Technologies segment, acquisitions and shareholder-friendly policies. However, rising costs and expenses are concerning.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Reference is made to the announcement by IDEX Biometrics ASA on 18 March 2025 regarding the results of the exercise of Warrants A. A total of 17,258 Warrants A were exercised, resulting in an aggregate subscription for 17,258 new shares, each Warrant A having an exercise price of NOK 0.15.

IDEX Biometrics ASA (“IDEX” or “Company”) released its preliminary financial statements for 2024 on 27 February 2025. Subsequently, on 11 March 2025, the Company announced its revised business strategy plan. The Company has reviewed its assets and business in view of this strategy. Certain equipment items have been written down and an obsolescence provision has been recognised on inventory, and other, minor adjustments have been made. The total effect for the IDEX Biometrics group on the consolidated result for 2024 and the consolidated net equity as of 31 December 2024 amounted to an increased loss of USD 1.6 million and lower equity by the same amount. This will be reflected in the annual financial statements for 2024 to be issued on 30 April 2025.

IDEX Biometrics ASA will hold an extraordinary general meeting (“EGM”) on Friday 11 April 2025 at 12.00 CET as an online meeting.  Reference is made to the announcement by IDEX Biometrics ASA (the "Company") on 11 March 2025 regarding the loan financing of NOK 30 million secured, proposed debt conversion, and amendment of Convertible Bond.

Issuer name: IDEX Biometrics ASA Ex. date: 11 March 2025 Type of corporate action: Possible subsequent offering (repair issue) This information is published in accordance with the requirements of the Continuing Obligations.